1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Cereno Scientific AB (publ)
  6. News
  7. Summary
    CRNO B   SE0008241558

CERENO SCIENTIFIC AB (PUBL)

(CRNO B)
  Report
End-of-day quote NORDIC GROWTH MARKET  -  05-17
3.870 SEK   +0.78%
05/12Cereno Scientific's Abstract on CS1's Innovative Phase II Study Design Accepted At Top Pulmonary Vascular Congress PVRI Held in June, 2022
CI
05/09Cereno Scientific to Present Candidate Drug CS585 Preclinical Data At EHA 2022 - the Premier Medical Congress for Hematology
CI
05/02CERENO SCIENTIFIC : nominates drug candidate CS014 in HDACi Program for continued development in cardiovascular disease
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cereno Scientific Obtains Additional Patent Protection for Phase II Drug Candidate CS1 in Japan

01/19/2022 | 02:15am EDT

Cereno Scientific announced strengthening of intellectual property rights (IPR) for drug candidate CS1 in the major market Japan. The patent is part of the third patent family which now has protection in Russia as well as Japan. It adds to the growing IPR portfolio for CS1 covering almost all global markets. The patent granted in Japan is part of Cereno's third patent family associated with drug candidate CS1 and is titled ‘Delayed release pharmaceutical formulations comprising valproic acid and uses thereof’. Drug candidate CS1 is currently undergoing a Phase II study for the rare disease pulmonary arterial hypertension (PAH) following investigational new drug (IND) acceptance from US FDA in September 2021. The aim of the study is to confirm CS1's safety, tolerability and efficacy in patients with PAH. It will be conducted at up to nine different clinical centers in USA with 30 participating patients.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
CERENO SCIENTIFIC AB (PUBL) 0.78% 3.87 End-of-day quote.-23.82%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) -2.23% 62.085 Delayed Quote.-14.26%
All news about CERENO SCIENTIFIC AB (PUBL)
05/12Cereno Scientific's Abstract on CS1's Innovative Phase II Study Design Accepted At Top ..
CI
05/09Cereno Scientific to Present Candidate Drug CS585 Preclinical Data At EHA 2022 - the Pr..
CI
05/02CERENO SCIENTIFIC : nominates drug candidate CS014 in HDACi Program for continued developm..
PU
05/02Cereno Scientific Nominates Drug Candidate CS014 in HDACi Program for Continued Develop..
CI
04/27CERENO SCIENTIFIC : nominates drug candidate CS585 in PCA Program for continued developmen..
PU
04/27Cereno Scientific Nominates Drug Candidate CS585 in PCA Program for Continued Developme..
CI
03/02CERENO SCIENTIFIC : solidifies CS1's patent protection with new European patent
PU
02/24Cereno Scientific Appoints Fredrik Frick as Head of Clinical Operations
CI
02/18INVITATION TO CERENO SCIENTIFIC WEBC : Clinical Phase II study with drug candidate CS1 in ..
PU
02/09Cereno Scientific AB Reports Earnings Results for the Fourth Quarter and Full Year Ende..
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 407 M 40,7 M 40,7 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 1
Free-Float 37,1%
Chart CERENO SCIENTIFIC AB (PUBL)
Duration : Period :
Cereno Scientific AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 3,87
Average target price
Spread / Average Target -
Managers and Directors
Sten Randahl Sörensen Chief Executive Officer
Daniel Brodén Chief Financial Officer
Eva Catharina Bäärnhielm Marklund Chairman
Björn Lennart Dahlöf Director & Chief Medical Officer
Niklas Olof Bergh Chief Scientific Officer & Deputy Director
Sector and Competitors
1st jan.Capi. (M$)
CERENO SCIENTIFIC AB (PUBL)-23.82%41
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169